Modification of focal cerebral ischemia by prostacyclin and indomethacin

I. Awad, J. R. Little, F. Lucas, V. Skrinska, R. Slugg, Ronald P Lesser

Research output: Contribution to journalArticle

Abstract

The object of this investigation was to study the effects of prostacyclin (PGI 2), with and without indomethacin, upon the evolution of cerebral infarction in the cat. Thirty-five fasted adult cats, lightly anesthetized with nitrous oxide, underwent right middle cerebral artery (MCA) occlusion. Eleven cats received an intracarotid infusion of 10 mg/ml PGI 2 in buffered saline, pH 10.5, at a rate of 0.01 ml/kg/min (100 ng/kg/min), 10 cats received the same infusion plus a single dose of intravenous indomethacin (4 mg/kg) in buffered saline, and 11 cats received intracarotid buffered saline, pH 10.5, at a rate of 0.01 ml/kg/min, without therapeutic agents. Treatment with PGI 2 was started upon MCA occlusion and continued for 6 hours, whereas indomethacin was given immediately prior to occlusion. Thirty minutes before perfusion, the animals were given fluorescein and Evans blue by intravenous injection. The cats were perfusion-fixed in vivo with carbon and buffered formalin 6 hours after MCA occlusion. Another five cats received tritium-labeled PGI 2, and peripheral venous samples were collected and assayed for PGI 2 and its alpha-keto metabolite. Mean arterial pressure was stable in treated animals during 6 hours of MCA occlusion, while untreated cats had significant (α = 0.05) progressive hypertension during that period. The regional cerebral blood flow (rCBF), measured by the intracarotid xenon-133 clearance method, decreased markedly in all animals immediately upon MCA occlusion. Untreated animals had a significant progressive improvement in rCBF during the occlusion period (α = 0.005), while treated animals had no such improvement. Quantitative electroencephalographic changes, gross edema, areas of fluorescein extravasation, and microscopic morphology (edema and infarct size) were not significantly different in the three groups. Prostacyclin appeared to reduce the extravasation of Evans blue dye. Systemic PGI 2 levels were significant despite intracarotid administration. The authors conclude that 1) intracarotid PGI 2 has a protective effect against the breakdown of the blood-brain barrier to protein-bound dyes seen in ischemic edema; 2) the systemic hemodynamic influence of PGI 2, in the presence of impaired autoregulation, may compromise rCBF in the ischemic zone and offset any direct beneficial effects; and 3) indomethacin fails to modify the effects of PGI 2.

Original languageEnglish (US)
Pages (from-to)714-719
Number of pages6
JournalJournal of Neurosurgery
Volume58
Issue number5
StatePublished - 1983
Externally publishedYes

Fingerprint

Epoprostenol
Brain Ischemia
Indomethacin
Cats
Middle Cerebral Artery Infarction
Cerebrovascular Circulation
Regional Blood Flow
Edema
Evans Blue
Fluorescein
Coloring Agents
Perfusion
Xenon
Tritium
Cerebral Infarction
Nitrous Oxide
Blood-Brain Barrier
Intravenous Injections
Formaldehyde
Arterial Pressure

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Awad, I., Little, J. R., Lucas, F., Skrinska, V., Slugg, R., & Lesser, R. P. (1983). Modification of focal cerebral ischemia by prostacyclin and indomethacin. Journal of Neurosurgery, 58(5), 714-719.

Modification of focal cerebral ischemia by prostacyclin and indomethacin. / Awad, I.; Little, J. R.; Lucas, F.; Skrinska, V.; Slugg, R.; Lesser, Ronald P.

In: Journal of Neurosurgery, Vol. 58, No. 5, 1983, p. 714-719.

Research output: Contribution to journalArticle

Awad, I, Little, JR, Lucas, F, Skrinska, V, Slugg, R & Lesser, RP 1983, 'Modification of focal cerebral ischemia by prostacyclin and indomethacin', Journal of Neurosurgery, vol. 58, no. 5, pp. 714-719.
Awad I, Little JR, Lucas F, Skrinska V, Slugg R, Lesser RP. Modification of focal cerebral ischemia by prostacyclin and indomethacin. Journal of Neurosurgery. 1983;58(5):714-719.
Awad, I. ; Little, J. R. ; Lucas, F. ; Skrinska, V. ; Slugg, R. ; Lesser, Ronald P. / Modification of focal cerebral ischemia by prostacyclin and indomethacin. In: Journal of Neurosurgery. 1983 ; Vol. 58, No. 5. pp. 714-719.
@article{c275b6f837824901a2caa250db269b9a,
title = "Modification of focal cerebral ischemia by prostacyclin and indomethacin",
abstract = "The object of this investigation was to study the effects of prostacyclin (PGI 2), with and without indomethacin, upon the evolution of cerebral infarction in the cat. Thirty-five fasted adult cats, lightly anesthetized with nitrous oxide, underwent right middle cerebral artery (MCA) occlusion. Eleven cats received an intracarotid infusion of 10 mg/ml PGI 2 in buffered saline, pH 10.5, at a rate of 0.01 ml/kg/min (100 ng/kg/min), 10 cats received the same infusion plus a single dose of intravenous indomethacin (4 mg/kg) in buffered saline, and 11 cats received intracarotid buffered saline, pH 10.5, at a rate of 0.01 ml/kg/min, without therapeutic agents. Treatment with PGI 2 was started upon MCA occlusion and continued for 6 hours, whereas indomethacin was given immediately prior to occlusion. Thirty minutes before perfusion, the animals were given fluorescein and Evans blue by intravenous injection. The cats were perfusion-fixed in vivo with carbon and buffered formalin 6 hours after MCA occlusion. Another five cats received tritium-labeled PGI 2, and peripheral venous samples were collected and assayed for PGI 2 and its alpha-keto metabolite. Mean arterial pressure was stable in treated animals during 6 hours of MCA occlusion, while untreated cats had significant (α = 0.05) progressive hypertension during that period. The regional cerebral blood flow (rCBF), measured by the intracarotid xenon-133 clearance method, decreased markedly in all animals immediately upon MCA occlusion. Untreated animals had a significant progressive improvement in rCBF during the occlusion period (α = 0.005), while treated animals had no such improvement. Quantitative electroencephalographic changes, gross edema, areas of fluorescein extravasation, and microscopic morphology (edema and infarct size) were not significantly different in the three groups. Prostacyclin appeared to reduce the extravasation of Evans blue dye. Systemic PGI 2 levels were significant despite intracarotid administration. The authors conclude that 1) intracarotid PGI 2 has a protective effect against the breakdown of the blood-brain barrier to protein-bound dyes seen in ischemic edema; 2) the systemic hemodynamic influence of PGI 2, in the presence of impaired autoregulation, may compromise rCBF in the ischemic zone and offset any direct beneficial effects; and 3) indomethacin fails to modify the effects of PGI 2.",
author = "I. Awad and Little, {J. R.} and F. Lucas and V. Skrinska and R. Slugg and Lesser, {Ronald P}",
year = "1983",
language = "English (US)",
volume = "58",
pages = "714--719",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "5",

}

TY - JOUR

T1 - Modification of focal cerebral ischemia by prostacyclin and indomethacin

AU - Awad, I.

AU - Little, J. R.

AU - Lucas, F.

AU - Skrinska, V.

AU - Slugg, R.

AU - Lesser, Ronald P

PY - 1983

Y1 - 1983

N2 - The object of this investigation was to study the effects of prostacyclin (PGI 2), with and without indomethacin, upon the evolution of cerebral infarction in the cat. Thirty-five fasted adult cats, lightly anesthetized with nitrous oxide, underwent right middle cerebral artery (MCA) occlusion. Eleven cats received an intracarotid infusion of 10 mg/ml PGI 2 in buffered saline, pH 10.5, at a rate of 0.01 ml/kg/min (100 ng/kg/min), 10 cats received the same infusion plus a single dose of intravenous indomethacin (4 mg/kg) in buffered saline, and 11 cats received intracarotid buffered saline, pH 10.5, at a rate of 0.01 ml/kg/min, without therapeutic agents. Treatment with PGI 2 was started upon MCA occlusion and continued for 6 hours, whereas indomethacin was given immediately prior to occlusion. Thirty minutes before perfusion, the animals were given fluorescein and Evans blue by intravenous injection. The cats were perfusion-fixed in vivo with carbon and buffered formalin 6 hours after MCA occlusion. Another five cats received tritium-labeled PGI 2, and peripheral venous samples were collected and assayed for PGI 2 and its alpha-keto metabolite. Mean arterial pressure was stable in treated animals during 6 hours of MCA occlusion, while untreated cats had significant (α = 0.05) progressive hypertension during that period. The regional cerebral blood flow (rCBF), measured by the intracarotid xenon-133 clearance method, decreased markedly in all animals immediately upon MCA occlusion. Untreated animals had a significant progressive improvement in rCBF during the occlusion period (α = 0.005), while treated animals had no such improvement. Quantitative electroencephalographic changes, gross edema, areas of fluorescein extravasation, and microscopic morphology (edema and infarct size) were not significantly different in the three groups. Prostacyclin appeared to reduce the extravasation of Evans blue dye. Systemic PGI 2 levels were significant despite intracarotid administration. The authors conclude that 1) intracarotid PGI 2 has a protective effect against the breakdown of the blood-brain barrier to protein-bound dyes seen in ischemic edema; 2) the systemic hemodynamic influence of PGI 2, in the presence of impaired autoregulation, may compromise rCBF in the ischemic zone and offset any direct beneficial effects; and 3) indomethacin fails to modify the effects of PGI 2.

AB - The object of this investigation was to study the effects of prostacyclin (PGI 2), with and without indomethacin, upon the evolution of cerebral infarction in the cat. Thirty-five fasted adult cats, lightly anesthetized with nitrous oxide, underwent right middle cerebral artery (MCA) occlusion. Eleven cats received an intracarotid infusion of 10 mg/ml PGI 2 in buffered saline, pH 10.5, at a rate of 0.01 ml/kg/min (100 ng/kg/min), 10 cats received the same infusion plus a single dose of intravenous indomethacin (4 mg/kg) in buffered saline, and 11 cats received intracarotid buffered saline, pH 10.5, at a rate of 0.01 ml/kg/min, without therapeutic agents. Treatment with PGI 2 was started upon MCA occlusion and continued for 6 hours, whereas indomethacin was given immediately prior to occlusion. Thirty minutes before perfusion, the animals were given fluorescein and Evans blue by intravenous injection. The cats were perfusion-fixed in vivo with carbon and buffered formalin 6 hours after MCA occlusion. Another five cats received tritium-labeled PGI 2, and peripheral venous samples were collected and assayed for PGI 2 and its alpha-keto metabolite. Mean arterial pressure was stable in treated animals during 6 hours of MCA occlusion, while untreated cats had significant (α = 0.05) progressive hypertension during that period. The regional cerebral blood flow (rCBF), measured by the intracarotid xenon-133 clearance method, decreased markedly in all animals immediately upon MCA occlusion. Untreated animals had a significant progressive improvement in rCBF during the occlusion period (α = 0.005), while treated animals had no such improvement. Quantitative electroencephalographic changes, gross edema, areas of fluorescein extravasation, and microscopic morphology (edema and infarct size) were not significantly different in the three groups. Prostacyclin appeared to reduce the extravasation of Evans blue dye. Systemic PGI 2 levels were significant despite intracarotid administration. The authors conclude that 1) intracarotid PGI 2 has a protective effect against the breakdown of the blood-brain barrier to protein-bound dyes seen in ischemic edema; 2) the systemic hemodynamic influence of PGI 2, in the presence of impaired autoregulation, may compromise rCBF in the ischemic zone and offset any direct beneficial effects; and 3) indomethacin fails to modify the effects of PGI 2.

UR - http://www.scopus.com/inward/record.url?scp=0020531387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020531387&partnerID=8YFLogxK

M3 - Article

C2 - 6339687

AN - SCOPUS:0020531387

VL - 58

SP - 714

EP - 719

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 5

ER -